AbCellera Biologics (ABCL) FCF Margin (2020 - 2026)
AbCellera Biologics (ABCL) reported FCF Margin of 449.24% for Q1 2026, up 7473.0% on a YoY basis from 5.93% in Q1 2025, and down 351.93% quarter-over-quarter from 99.4% in Q4 2025.
AbCellera Biologics (ABCL) FCF Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported FCF Margin for 7 years, with the latest figure at 449.24% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 7473.0% year-over-year to 449.24%; the trailing twelve-month figure through Mar 2026 stood at 238.91% (up 38101.0% YoY), and the FY2025 full-year result was 231.69%, up 41670.0% from the prior year.
- FCF Margin for Q1 2026 stood at 449.24%, down from 99.4% in the prior quarter.
- The five-year high for FCF Margin was 526.37% in Q2 2022, with the low at 728.42% in Q3 2024.
- Historically, FCF Margin has averaged 312.02% across 5 years, with a median of 370.87% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 61124 bps — and 2025, when it jumped 41591 bps.
- AbCellera Biologics' FCF Margin stood at 86.25% in 2022, then tumbled by 530 bps to 370.87% in 2023, then slipped by 26 bps to 467.92% in 2024, then surged by 79 bps to 99.4% in 2025, then slumped by 352 bps to 449.24% in 2026.
- The last three FCF Margin figures came in at 449.24% (Q1 2026), 99.4% (Q4 2025), and 687.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -449.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -449.24% |
| Dec 31, 2025 | -99.40% |
| Sep 30, 2025 | -687.01% |
| Jun 30, 2025 | -267.91% |
| Mar 31, 2025 | -523.97% |
| Dec 31, 2024 | -467.92% |
| Sep 30, 2024 | -728.42% |
| Jun 30, 2024 | -683.82% |
| Mar 31, 2024 | -661.52% |
| Dec 31, 2023 | -370.87% |
| Sep 30, 2023 | -309.70% |
| Jun 30, 2023 | -72.57% |
| Mar 31, 2023 | -484.31% |
| Dec 31, 2022 | 86.25% |
| Sep 30, 2022 | -137.40% |
| Jun 30, 2022 | 526.37% |
| Mar 31, 2022 | 27.08% |
| Dec 31, 2021 | -18.76% |
| Sep 30, 2021 | -263.36% |
| Jun 30, 2021 | 437.29% |